Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
- Sprache
-
Englisch
- Umfang
-
Online-Ressource
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Erschienen in
-
In: Annals of Oncology 25.12 (2014): S. 2363-2372.
- Schlagwort
-
-
Krebs
Onkologie
- Urheber
-
Minckwitz, G. von
Loibl, S.
Untch, M.
Eidtmann, H.
Rezai, M.
Fasching, Peter A.
Tesch, H.
Eggemann, H.
Schrader, I.
Kittel, K.
Hanusch, C.
Huober, J.
Solbach, C.
Jackisch, C.
Kunz, G.
Blohmer, J. U.
Hauschild, M.
Fehm, T.
Nekljudova, V.
Gerber, B.
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2016
- URN
-
urn:nbn:de:bvb:29-opus4-74543
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:53 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Minckwitz, G. von
- Loibl, S.
- Untch, M.
- Eidtmann, H.
- Rezai, M.
- Fasching, Peter A.
- Tesch, H.
- Eggemann, H.
- Schrader, I.
- Kittel, K.
- Hanusch, C.
- Huober, J.
- Solbach, C.
- Jackisch, C.
- Kunz, G.
- Blohmer, J. U.
- Hauschild, M.
- Fehm, T.
- Nekljudova, V.
- Gerber, B.
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2016
Ähnliche Objekte (12)
Bevacizumab (Avastin) : effektive zielgerichtete Therapie des HER2-negativen metastasierten Mammakarzinoms
Everolimus plus Exemestan : Erweiterung der endokrinen Therapiepalette beim fortgeschrittenen HR+, HER2-Mammakarzinom
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT HER2+/HR− trial
Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial [[Elektronische Ressource]]
Early modulation of circulating MicroRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: A cost estimate with real-world data
Sichere Anwendung von Everolimus
Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients—sequentially, or better simultaneously?
Bevacizumab (Avastin) : effektive zielgerichtete Therapie des HER2-negativen metastasierten Mammakarzinoms
Everolimus plus Exemestan : Erweiterung der endokrinen Therapiepalette beim fortgeschrittenen HR+, HER2-Mammakarzinom
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT HER2+/HR− trial
Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial [[Elektronische Ressource]]
Early modulation of circulating MicroRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: A cost estimate with real-world data
Sichere Anwendung von Everolimus
Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients—sequentially, or better simultaneously?
Bevacizumab (Avastin) : effektive zielgerichtete Therapie des HER2-negativen metastasierten Mammakarzinoms
Everolimus plus Exemestan : Erweiterung der endokrinen Therapiepalette beim fortgeschrittenen HR+, HER2-Mammakarzinom
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT HER2+/HR− trial
Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial [[Elektronische Ressource]]
Early modulation of circulating MicroRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: A cost estimate with real-world data
Sichere Anwendung von Everolimus